Ruxotemitide | CAS#1345407-05-7 | Amphipathic Cationic Peptide

MedKoo Cat#: 527723 | Name: Ruxotemitide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ruxotemitide, also known as LTX-315, is an amphipathic cationic peptide potentially for the treatment of melanoma, breast cancer, head and neck cancer and lymphoma. Ruxotemitide has been shown to be inefficient in stimulating mitophagy and may trigger unregulated necrosis. Ruxotemitide can trigger mitochondrial permeabilization and subsequent cell death.

Chemical Structure

Ruxotemitide

CAS#1345407-05-7

Theoretical Analysis

MedKoo Cat#: 527723

Name: Ruxotemitide

CAS#: 1345407-05-7

Chemical Formula: C78H106N18O9

Exact Mass: 1438.8390

Molecular Weight: 1439.82

Elemental Analysis: C, 65.07; H, 7.42; N, 17.51; O, 10.00

Price and Availability

Size	Price	Availability
5mg	USD 350.00	2 Weeks
10mg	USD 550.00	2 Weeks
25mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

LTX-315; LTX 315; LTX315; Ruxotemitide

IUPAC/Chemical Name

(S)-2,6-diamino-N-((5S,8S,11S,14S,17S,20S,23S,26S)-11,20,23-tris((1H-indol-3-yl)methyl)-1,30-diamino-14,17-bis(4-aminobutyl)-8-benzhydryl-5-carbamoyl-7,10,13,16,19,22,25-heptaoxo-6,9,12,15,18,21,24-heptaazatriacontan-26-yl)hexanamide

InChi Key

GGAKLYWEFZCVIT-TVEKFXMRSA-N

InChi Code

InChI=1S/C78H106N18O9/c79-38-18-13-30-57(84)71(98)90-62(35-15-20-40-81)73(100)93-66(44-52-47-87-59-32-11-8-28-55(52)59)76(103)95-65(43-51-46-86-58-31-10-7-27-54(51)58)75(102)92-63(36-16-21-41-82)72(99)91-64(37-17-22-42-83)74(101)94-67(45-53-48-88-60-33-12-9-29-56(53)60)77(104)96-69(78(105)89-61(70(85)97)34-14-19-39-80)68(49-23-3-1-4-24-49)50-25-5-2-6-26-50/h1-12,23-29,31-33,46-48,57,61-69,86-88H,13-22,30,34-45,79-84H2,(H2,85,97)(H,89,105)(H,90,98)(H,91,99)(H,92,102)(H,93,100)(H,94,101)(H,95,103)(H,96,104)/t57-,61-,62-,63-,64-,65-,66-,67-,69-/m0/s1

SMILES Code

NCCCC[C@@H](C(N)=O)NC([C@H](C(C1=CC=CC=C1)C2=CC=CC=C2)NC([C@H](CC3=CNC4=C3C=CC=C4)NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CC5=CNC6=C5C=CC=C6)NC([C@H](CC7=CNC8=C7C=CC=C8)NC([C@H](CCCCN)NC([C@H](CCCCN)N)=O)=O)=O)=O)=O)=O)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Studies have shown that Ruxotemitide causes immediate arrest of mitochondrial respiration without any major uncoupling effect. Accordingly, Ruxotemitide disrupts the mitochondrial network, dissipates the mitochondrial inner transmembrane potential, and causes release of mitochondrial intermembrane proteins into the cytosol.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,439.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhou H, Forveille S, Sauvat A, Sica V, Izzo V, Durand S, Müller K, Liu P, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G. The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization. Oncotarget. 2015 Sep 29;6(29):26599-614. doi: 10.18632/oncotarget.5613. PubMed PMID: 26378049; PubMed Central PMCID: PMC4694939. 2: Forveille S, Zhou H, Sauvat A, Bezu L, Müller K, Liu P, Zitvogel L, Pierron G, Rekdal Ø, Kepp O, Kroemer G. The oncolytic peptide LTX-315 triggers necrotic cell death. Cell Cycle. 2015;14(21):3506-12. doi: 10.1080/15384101.2015.1093710. PubMed PMID: 26566869; PubMed Central PMCID: PMC4825625. 3: Haug BE, Camilio KA, Eliassen LT, Stensen W, Svendsen JS, Berg K, Mortensen B, Serin G, Mirjolet JF, Bichat F, Rekdal Ø. Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide. J Med Chem. 2016 Apr 14;59(7):2918-27. doi: 10.1021/acs.jmedchem.5b02025. PubMed PMID: 26982623. 4: Zhou H, Forveille S, Sauvat A, Yamazaki T, Senovilla L, Ma Y, Liu P, Yang H, Bezu L, Müller K, Zitvogel L, Rekdal Ø, Kepp O, Kroemer G. The oncolytic peptide LTX-315 triggers immunogenic cell death. Cell Death Dis. 2016 Mar 10;7:e2134. doi: 10.1038/cddis.2016.47. PubMed PMID: 26962684; PubMed Central PMCID: PMC4823948. 5: Yamazaki T, Pitt JM, Vétizou M, Marabelle A, Flores C, Rekdal Ø, Kroemer G, Zitvogel L. The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ. 2016 Jun;23(6):1004-15. doi: 10.1038/cdd.2016.35. PubMed PMID: 27082453; PubMed Central PMCID: PMC4987735. 6: Eike LM, Yang N, Rekdal Ø, Sveinbjørnsson B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells. Oncotarget. 2015 Oct 27;6(33):34910-23. doi: 10.18632/oncotarget.5308. PubMed PMID: 26472184; PubMed Central PMCID: PMC4741498. 7: Camilio KA, Berge G, Ravuri CS, Rekdal O, Sveinbjørnsson B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315. Cancer Immunol Immunother. 2014 Jun;63(6):601-13. doi: 10.1007/s00262-014-1540-0. PubMed PMID: 24676901; PubMed Central PMCID: PMC4024132. 8: Camilio KA, Rekdal O, Sveinbjörnsson B. LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent. Oncoimmunology. 2014 Jun 25;3:e29181. PubMed PMID: 25083333; PubMed Central PMCID: PMC4108458. 9: Sistigu A, Manic G, Vitale I. LTX-315, CAPtivating immunity with necrosis. Cell Cycle. 2016 May 2;15(9):1176-7. doi: 10.1080/15384101.2016.1160609. PubMed PMID: 26986689; PubMed Central PMCID: PMC4889301. 10: O’Reilly, S. (2024). Targeting pro-fibrotic macrophages with bioactive self-assembly peptides to retard kidney fibrosis–know thyself. Cellular & molecular immunology, 1-3.